When to conduct hepatic impairment studies and when modeling may be enough Blog When to conduct hepatic impairment studies and when modeling may be enough How to decide if a hepatic impairment study is required, choose the right study design,…Zoe BarterJuly 13, 2026
Dosimetry for radiopharmaceutical therapy: From measurement to dose justification Blog Dosimetry for radiopharmaceutical therapy: From measurement to dose justification Why dosimetry for radiopharmaceutical therapy needs more than absorbed dose. How BED, radiation dosimetry &…Hunter Stephens, PhDJuly 7, 2026
Population PK Modeling Supporting the Aripiprazole Two-Injection Start Regimen in Japanese Patients Publication Population PK Modeling Supporting the Aripiprazole Two-Injection Start Regimen in Japanese Patients Learn how population PK modeling and simulation supported a regulatory strategy for a simplified aripiprazole…Danielle PillsburyJuly 7, 2026
Pharmacokinetics of Fentanyl and Norfentanyl in a Rat Model of Fixed-Volume Hemorrhagic Shock Publication Pharmacokinetics of Fentanyl and Norfentanyl in a Rat Model of Fixed-Volume Hemorrhagic Shock Learn how a fixed-volume rat shock model shows increased fentanyl exposure and impaired clearance, analyzed…CertaraJuly 4, 2026
5 Key Principles of Modern PK/PD in 2026 Guide 5 Key Principles of Modern PK/PD in 2026 Explore other Phoenix solutions to enhance your PK/PD workflow and discover how Phoenix helps you…CertaraJune 30, 2026
Enhancing clinical trials with real-world evidence in pregnancy research Blog Enhancing clinical trials with real-world evidence in pregnancy research Learn how real-world evidence improves clinical trials in pregnancy by enhancing safety data, trial design,…Alekhya Lavu, PhD, PharmDJune 26, 2026
Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development Announcement Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development Integrated offering combines drug development, regulatory, commercial, and investor strategy expertise to help early-stage biotech…Danielle PillsburyJune 23, 2026
63 runs and no convergence: When RsNLME succeeded where other PK/PD solutions couldn’t BlogCase Study 63 runs and no convergence: When RsNLME succeeded where other PK/PD solutions couldn’t After 63 failed runs on a 16-ODE neutropenia model, RsNLME achieved PK/PD convergence on the…Stephen DuffullJune 23, 2026
Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study Poster Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study Learn how Certara's IO Simulator was used to predict efficacy, cytokine release syndrome risk, and…CertaraJune 23, 2026
Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab Poster Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab Discover how Quantitative Systems Pharmacology (QSP) was used to predict cytokine release syndrome risk and…CertaraJune 23, 2026